Abstract
Huntington and related neurological diseases result from expansion of a polyglutamine (polyQ) tract. The linear lattice model for the structure and binding properties of polyQ proposes that both expanded and normal polyQ tracts in the preaggregation state are random-coil structures but that an expanded polyQ repeat contains a larger number of epitopes recognized by antibodies or other proteins. The crystal structure of polyQ bound to MW1, an antibody against polyQ, reveals that polyQ adopts an extended, coil-like structure. Consistent with the linear lattice model, multimeric MW1 Fvs bind more tightly to longer than to shorter polyQ tracts and, compared with monomeric Fv, bind expanded polyQ repeats with higher apparent affinities. These results suggest a mechanism for the toxicity of expanded polyQ and a strategy to link anti-polyQ compounds to create high-avidity therapeutics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
08 May 2007
reference added and extra author corr address deleted
Notes
*NOTE: In the version of this article initially published, the incorrect corresponding authors were listed. The corresponding author should be Pingwei Li (pingwei@neo.tamu.edu). We apologize for this mistake.
In addition, a paper was not cited. The missing citation is:
49. Altschuler, E.L., Hud, N.V., Mazrimas, J.A. & Rupp, B. Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. J. Pept. Res. 50, 73–75 (1997).
The citation should appear on page 381, in the eighth sentence of the article’s second paragraph, as follows: “However, studies involving polyQ peptides 14,26-28,49 , and our studies using polyQ tracts in the context of the HD exon 1 protein 29 , demonstrated that the predominant species of both normal and expanded unaggregated polyQ in solution is an extended random coil and showed no evidence for a detectable population of expanded soluble polyQ molecules with global conformational differences from normal polyQ.”
These errors have been corrected in the HTML and PDF versions of the article.
References
Ross, C.A. Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35, 819–822 (2002).
Zoghbi, H.Y. & Orr, H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217–247 (2000).
Wanker, E.E. Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations. Biol. Chem. 381, 937–942 (2000).
Masino, L. & Pastore, A. A structural approach to trinucleotide expansion diseases. Brain Res. Bull. 56, 183–189 (2001).
Perutz, M.F., Finch, J.T., Berriman, J. & Lesk, A. Amyloid fibers are water-filled nanotubes. Proc. Natl. Acad. Sci. USA 99, 5591–5595 (2002).
Perutz, M.F., Pope, B.J., Owen, D., Wanker, E.E. & Scherzinger, E. Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques. Proc. Natl. Acad. Sci. USA 99, 5596–5600 (2002).
Thakur, A.K. & Wetzel, R. Mutational analysis of the structural organization of polyglutamine aggregates. Proc. Natl. Acad. Sci. USA 99, 17014–17019 (2002).
Thakur, A.K., Yang, W. & Wetzel, R. Inhibition of polyglutamine aggregate cytotoxicity by a structure-based elongation inhibitor. FASEB J. 18, 923–925 (2004).
Sikorski, P. & Atkins, E. New model for crystalline polyglutamine assemblies and their connection with amyloid fibrils. Biomacromolecules 6, 425–432 (2005).
Sharma, D., Shinchuk, L.M., Inouye, H., Wetzel, R. & Kirschner, D.A. Polyglutamine homopolymers having 8–45 residues form slablike beta-crystallite assemblies. Proteins 61, 398–411 (2005).
Baxa, U. et al. Filaments of the Ure2p prion protein have a cross-beta core structure. J. Struct. Biol. 150, 170–179 (2005).
Nelson, R. & Eisenberg, D. Recent atomic models of amyloid fibril structure. Curr. Opin. Struct. Biol. 16, 260–265 (2006).
Li, S.-H. et al. Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol. 22, 1277–1287 (2002).
Chen, S., Berthelier, V., Yang, W. & Wetzel, R. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol. 311, 173–182 (2001).
Lescure, A. et al. The N-terminal domain of the human TATA-binding protein plays a role in transcription from TATA-containing RNA polymerase II and III promoters. EMBO J. 13, 1166–1175 (1994).
Trottier, Y. et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378, 403–406 (1995).
Huang, C.C. et al. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins. Somat. Cell Mol. Genet. 24, 217–233 (1998).
Persichetti, F. et al. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment. Neurobiol. Dis. 6, 364–375 (1999).
Foley, S., Curtis, J., Saudou, F. & Finkbeiner, S. Immunodominant pathological polyglutamine epitope. Soc. Neurosci. 26, 1294 (2000).
Peters-Libeu, C. et al. Crystallization and diffraction properties of the Fab fragment of 3B5H10, an antibody specific for disease-causing polyglutamine stretches. Acta Crystallograph. Sect. F Struct. Biol. Cryst. Commun. 61, 1065–1068 (2005).
Ko, J., Ou, S. & Patterson, P.H. New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res. Bull. 56, 319–329 (2001).
Trottier, Y. et al. Heterogeneous intracellular localization and expression of ataxin-3. Neurobiol. Dis. 5, 335–347 (1998).
Peters, M.F. & Ross, C.A. Isolation of a 40-kDa Huntingtin-associated protein. J. Biol. Chem. 276, 3188–3194 (2001).
Kazantsev, A. et al. A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat. Genet. 30, 367–376 (2002).
Tobin, A.J. & Signer, E.R. Huntington's disease: the challenge for cell biologists. Trends Cell Biol. 10, 531–536 (2000).
Masino, L., Kelly, G., Leonard, K., Trottier, Y. & Pastore, A. Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett. 513, 267–272 (2002).
Chen, S., Ferrone, F.A. & Wetzel, R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl. Acad. Sci. USA 99, 11884–11889 (2002).
Bhattacharyya, A.M., Thakur, A.K. & Wetzel, R. Polyglutamine aggregation nucleation: thermodynamics of a highly unfavorable protein folding reaction. Proc. Natl. Acad. Sci. USA 102, 15400–15405 (2005).
Bennett, M.J. et al. A linear lattice model for polyglutamine in CAG-expansion diseases. Proc. Natl. Acad. Sci. USA 99, 11634–11639 (2002).
McGhee, J.D. & von Hippel, P.H. Theoretical aspects of DNA-protein interactions: co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. J. Mol. Biol. 86, 469–489 (1974).
Sambashivan, S., Liu, Y., Sawaya, M.R., Gingery, M. & Eisenberg, D. Amyloid-like fibrils of ribonuclease A with three-dimensional domain-swapped and native-like structure. Nature 437, 266–269 (2005).
Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87, 493–506 (1996).
Sanchez, P., Marche, P.N., Rueff-Juy, D. & Cazenave, P.A. Mouse V lambda x gene sequence generates no junctional diversity and is conserved in mammalian species. J. Immunol. 144, 2816–2820 (1990).
Adzhubei, A.A. & Sternberg, M.J.E. Left-handed polyproline II helices commonly occur in globular proteins. J. Mol. Biol. 229, 472–493 (1993).
Chellgren, B.W., Miller, A.-F. & Creamer, T.P. Evidence for polyproline II helical structure in short polyglutamine tracts. J. Mol. Biol. 361, 362–371 (2006).
Creamer, T.P. & Campbell, M.N. Determinants of the polyproline II helix from modeling studies. Adv. Protein Chem. 62, 263–282 (2002).
Wang, X., Vitalis, A., Wyczalkowski, M.A. & Pappu, R.V. Characterizing the conformational ensemble of monomeric polyglutamine. Proteins 63, 297–311 (2006).
Perisic, O., Webb, P.A., Holliger, P., Winter, G. & Williams, R.L. Crystal structure of a diabody, a bivalent antibody fragment. Structure 2, 1217–1226 (1994).
Katz, B.A. Binding of biotin to streptavidin stabilizes intersubunit salt bridges between Asp61 and His87 at low pH. J. Mol. Biol. 274, 776–800 (1997).
Khoshnan, A., Ko, J. & Patterson, P.H. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. USA 99, 1002–1007 (2002).
Kelly, R.C., Jensen, D.E. & von Hipple, P.H. DNA “melting” proteins. IV. Fluorescence measurements of binding parameters for bacteriophage T4 gene 32-protein to mono-, oligo-, and polynucleotides. J. Biol. Chem. 251, 7240–7250 (1976).
Sundberg, E. & Mariuzza, R. Molecular recognition in antibody-antigen complexes. Adv. Protein Chem. 61, 119–160 (2002).
Dunah, A.W. et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238–2243 (2002).
Heiser, V. et al. Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy. Proc. Natl. Acad. Sci. USA 97, 6739–6744 (2000).
Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763 (1994).
Brünger, A.T. et al. Crystallography & NMR System: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905–921 (1998).
Lawrence, M.C. & Colman, P.M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946–950 (1993).
Altschuh, D., Vix, O., Rees, B. & Thierry, J.C. A conformation of cyclosporin A in aqueous environment revealed by the X-ray structure of a cyclosporin-Fab complex. Science 256, 92–94 (1992).
Altschuler, E.L., Hud, N.V., Mazrimas, J.A. & Rupp, B. Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. J. Pept. Res. 50, 73–75 (1997).
Acknowledgements
We thank A. Khoshnan and P.H. Patterson (California Institute of Technology) for the MW1 genes and hybridoma cell line, R. Wetzel (University of Tennessee Medical Center) for polyQ peptides, S. Sambashivan and D. Eisenberg (University of California, Los Angeles) for the RNase-10Q construct, D. King and A. Falick at the Howard Hughes Medical Institutes Mass Spectrometry Laboratory at University of California, Berkeley for the analysis of the MW1 Fab and A.B. Herr, A. Khoshnan, P.H. Patterson and members of the Bjorkman laboratory for comments on the manuscript. This work was supported by grants from the Huntington's Disease Society of America and the Howard Hughes Medical Institute (P.J.B.) and by start-up funds from Texas A&M University (P.L.).
Author information
Authors and Affiliations
Contributions
P.L., M.J.B. and P.J.B. conceived the experiments. P.L. expressed the MW1 Fvs and solved the MW1 and MW1–GQ10G structures. K.E.H.-T. purified polyQ proteins, prepared MW1 Fabs and conducted crystallization trials for the MW1 Fab. T.G. and X.L. constructed and expressed SUMO-10Q and crystallized the MW1–GQ10G complex. P.L. and A.P.W. performed and analyzed the surface plasmon resonance experiments. P.L., M.J.B. and P.J.B. wrote the paper. All authors discussed and interpreted the results and commented on the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Fig. 1
MW1 sequence and comparison with other antibodies (PDF 99 kb)
Supplementary Fig. 2
Gel-filtration chromatography profiles (PDF 215 kb)
Supplementary Fig. 3
Structure comparisons (PDF 1213 kb)
Supplementary Fig. 4
Surface plasmon resonance binding data (PDF 218 kb)
Supplementary Table 1
MW1-polyQ interactions (PDF 84 kb)
Rights and permissions
About this article
Cite this article
Li, P., Huey-Tubman, K., Gao, T. et al. The structure of a polyQ–anti-polyQ complex reveals binding according to a linear lattice model. Nat Struct Mol Biol 14, 381–387 (2007). https://doi.org/10.1038/nsmb1234
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nsmb1234
This article is cited by
-
Salivary Huntingtin protein is uniquely associated with clinical features of Huntington’s disease
Scientific Reports (2023)
-
Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies
Scientific Reports (2023)
-
The structure of pathogenic huntingtin exon 1 defines the bases of its aggregation propensity
Nature Structural & Molecular Biology (2023)
-
Assessing average somatic CAG repeat instability at the protein level
Scientific Reports (2019)
-
Polyglutamine expansion affects huntingtin conformation in multiple Huntington’s disease models
Scientific Reports (2017)